Accounting for Population Heterogeneity Over-Time in Estimating Costs and Outcomes in Cohort-Based Health-Economic Evaluations

Author(s)

Felizzi F1, Manevy F2, Di Maio D2
1Novartis, Basel, BS, Switzerland, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland

OBJECTIVES: In cohort-based approaches to cost-effectiveness analyses, the way the impact of demographics characteristics on outcomes is modeled has a large impact on the results over long-time horizons. Methods based on both means and full distributions of demographic characteristics have been presented. However, both omit to re-adjust such parameters or distributions over time to account for individuals experiencing an event (e.g. death or discontinuation) and will thus not contribute anymore to the demographic characteristics of the rest of the cohort for estimating quantities of interest.

METHODS: We present an approach that accounts for change in population heterogeneity over time. At discrete time points in economic models, we re-set key population demographics to a new baseline accounting for subjects that are no longer part of the model cohort, e.g. subjects who experienced a death event are excluded from the calculation of background mortality.

RESULTS: A series of simulations shows how differences in the change of age and weight distributions (among other factors considered) over time can significantly affect long-term clinical and cost outcomes in the case of identical Kaplan-Meier curves (or survival patterns). For diseases that can affect people in all age groups, accurate estimates of long-term life-year gains will depend on whether deaths are predominantly experienced by younger or older individuals within the cohort, as this will have a profound impact on background mortality risk over time which will in turn lead to significantly different long-term results. Similar considerations can apply to drug costs and weight distributions.

CONCLUSIONS: The implementation of changing population heterogeneity has been shown to impact the prediction of long-term outcomes in health-economic models. Here we suggest re-setting the demographic characteristics after events to further improve model accuracy. This approach has the potential to be extended to analyses of specific external populations of interest by means of propensity score methods.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)

Code

POSA74

Topic

Economic Evaluation, Health Technology Assessment

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Decision & Deliberative Processes

Disease

No Specific Disease

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×